△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Concepts
SIRT6 activation protects retinal neurons in glaucoma
Primary
Galilei Biosciences' lead causal theory is that small-molecule activation of SIRT6 can protect retinal ganglion cells and the optic nerve from degeneration in glaucoma, an age-related neurodegenerative eye disease. The proposed intervention is a proprietary SIRT6 activator optimized through medicinal chemistry and ADME/PK work for in vivo proof of concept and development-candidate nomination.
Testable predictions are that SIRT6 activators should preserve retinal ganglion cell survival, reduce optic nerve degeneration, and improve glaucoma-relevant structural or functional endpoints in aging or glaucoma models compared with untreated controls.
The core premise is credible: glaucoma involves retinal ganglion cell and optic nerve degeneration, and the cited 2024 ocular paper directly says SIRT6 protects those tissues during aging and glaucoma. The weaker part is pharmacology. A target can be protective genetically or biologically and still fail as a drug target if the compound does not reach the retina and optic nerve at the right exposure, potency, selectivity, and tolerability.
Supporting evidence: The evidence context cites "Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma" from 2024.; Glaucoma is described as an age-related neurodegenerative eye disease involving retinal ganglion cell and optic nerve degeneration.; Multiple papers support SIRT6 as a tractable small-molecule target, including cellularly active allosteric activators and pyrrolo[1,2-a]quinoxaline-based activators.
Counter evidence: The evidence does not show that Galilei's proprietary activator achieves sufficient retinal or optic nerve exposure in vivo.; Much of the supporting SIRT6 biology comes from non-ocular systems such as liver failure, diabetic heart failure, wound healing, cartilage, and lifespan models.; The theory depends on translating target biology into a drug effect, and that bridge is still an assumption.
Explanatory power6.0
The theory explains the supplied ocular observation fairly well: if SIRT6 protects retinal ganglion cells and optic nerve tissue, then activating SIRT6 could plausibly slow glaucoma-like degeneration. It does not yet beat alternative explanations decisively. The observed protection could reflect developmental, genetic, stress-response, inflammatory, metabolic, or model-specific effects rather than a clean pharmacologic SIRT6 activation pathway.
Supporting evidence: The 2024 ocular publication directly links SIRT6 to protection of retinal ganglion cells and optic nerve during aging and glaucoma.; SIRT6 has reported roles in DNA damage repair, energy homeostasis, inflammation, metabolism, and tissue protection, all plausible contributors to neuronal survival.; The proposed predictions align with the disease anatomy: retinal ganglion cell survival, optic nerve degeneration, and glaucoma-relevant structural or functional endpoints.
Counter evidence: The evidence context does not report head-to-head testing against alternative neuroprotective mechanisms.; Non-ocular SIRT6 repair findings do not prove that the same mechanism explains glaucomatous neurodegeneration.; The proprietary activator has not yet been shown here to reproduce the ocular SIRT6-protection phenotype.
Falsifiability8.0
This is a testable theory. It predicts measurable effects in aging or glaucoma models: preserved retinal ganglion cell survival, reduced optic nerve degeneration, and better structural or functional endpoints versus untreated controls. A well-run in vivo experiment could break the theory plainly: adequate SIRT6 activation and ocular exposure, but no protection. That would hurt.
Supporting evidence: The theory specifies retinal ganglion cell survival as an outcome.; The theory specifies optic nerve degeneration as an outcome.; The theory specifies glaucoma-relevant structural or functional endpoints compared with untreated controls.; The development plan includes medicinal chemistry and ADME/PK work for in vivo proof of concept.
Counter evidence: The prediction does not specify exact effect sizes, dosing thresholds, exposure targets, model types, or timepoints.; Without target engagement assays in retinal and optic nerve tissue, a negative result could be blamed on exposure rather than the causal theory.
Reasoning tree
premise
Small-molecule activation of SIRT6 can protect retinal ganglion cells and the optic nerve from degeneration in glaucoma.
medium confidence - 1 linked evidence item
observation
observed_in
SIRT6 protects retinal ganglion cells and the optic nerve from degeneration during aging and glaucoma.
high confidence - 1 linked evidence item
premise
assumes
Glaucoma is an age-related neurodegenerative eye disease involving retinal ganglion cell and optic nerve degeneration.
high confidence - 2 linked evidence items
premise
assumes
Current glaucoma detection, diagnosis, monitoring, treatment, and mechanistic understanding have unmet needs.
medium confidence - 1 linked evidence item
premise
requires
SIRT6 is a biologically and catalytically tractable target for small-molecule modulation.
medium confidence - 3 linked evidence items
observation
observed_in
Cellularly active allosteric SIRT6 activators have been identified.
high confidence - 1 linked evidence item
observation
observed_in
Potent and selective pyrrolo[1,2-a]quinoxaline-based SIRT6 activators have been designed, synthesized, and pharmacologically evaluated.
medium confidence - 1 linked evidence item
premise
implies
SIRT6 activity is broadly linked to age-related tissue protection, repair, metabolism, inflammation, and lifespan biology.
medium confidence - 7 linked evidence items
observation
observed_in
SIRT6 activation can rescue age-related decline in DNA damage repair in primary human chondrocytes.
medium confidence - 1 linked evidence item
observation
observed_in
Restoring SIRT6-linked energy homeostasis can extend healthy lifespan in experimental models.
medium confidence - 2 linked evidence items
observation
observed_in
SIRT6 activation has shown protective or reparative effects in non-ocular disease models, including liver failure, diabetic heart failure, wound healing, and osteoarthritis-relevant biology.
medium confidence - 4 linked evidence items
assumption
requires
A proprietary SIRT6 activator can achieve sufficient retinal and optic nerve exposure, potency, selectivity, and tolerability in vivo to test neuroprotection in glaucoma models.
medium confidence - 2 linked evidence items
project_implication
implies
Medicinal chemistry and ADME/PK optimization should prioritize an in vivo SIRT6 activator suitable for proof of concept and development-candidate nomination.
medium confidence - 1 linked evidence item
derivation
implies
If SIRT6 causally protects retinal ganglion cells and optic nerve tissue, then pharmacologic SIRT6 activation should be disease-modifying in glaucoma models.
medium confidence - 2 linked evidence items
prediction
predicts
SIRT6 activators should preserve retinal ganglion cell survival in aging or glaucoma models compared with untreated controls.
medium confidence - 1 linked evidence item
prediction
predicts
SIRT6 activators should reduce optic nerve degeneration in aging or glaucoma models compared with untreated controls.
medium confidence - 1 linked evidence item
prediction
predicts
SIRT6 activators should improve glaucoma-relevant structural or functional endpoints in aging or glaucoma models compared with untreated controls.
medium confidence - 2 linked evidence items
Public endorsements
silent
There is no public evidence here that Beth Werner endorsed, discussed, or contradicted the SIRT6-in-glaucoma theory. With no quotes, records, or publications attached, the defensible call is silence.
silent
No public quotes, records, or publications were provided that tie David P. Al-Adra to this SIRT6-in-glaucoma theory. With no cited public statement either supporting, discussing, or disputing it, the correct classification is silence.
silent
The provided public evidence shows David Sinclair discussing aging, epigenetic information loss, and calorie restriction, but nothing here mentions SIRT6 activation, glaucoma, retinal ganglion cells, optic nerve protection, or Galilei's ocular neuroprotection theory. On this record, he is publicly silent on the specific theory.
silent
The public evidence ties John Denu to Galilei as a co-founder and to broad research on epigenetics, metabolism, and signaling, and one public post says Galilei is developing sirtuin drugs. It does not show him publicly endorsing, describing, or disputing the specific claim that SIRT6 activation protects retinal ganglion cells or optic nerve tissue in glaucoma.
The public evidence ties Guarente to aging, neurodegeneration, and sirtuin research in general, but nothing here shows him publicly discussing Galilei's specific claim that SIRT6 activation protects retinal ganglion cells or the optic nerve in glaucoma. Founder status alone is not a public endorsement of this exact theory.
Galilei's development plan centers on proprietary small-molecule SIRT6 activators, including stabilized RM-13 analogs, MDL analogs, and the CL5D series. The causal theory is not only that SIRT6 is protective, but that optimized drug-like activators can produce sufficient exposure, potency, selectivity, and pharmacokinetics to translate SIRT6 biology into a practical therapy for glaucoma and potentially other age-related diseases.
Testable predictions are that medicinal chemistry and ADME/PK optimization should yield compounds with improved SIRT6 activation, acceptable pharmacokinetic exposure, in vivo target engagement, and efficacy in glaucoma proof-of-concept models.
The premise is credible: SIRT6 has protective biology in aging-linked tissue degeneration, and small molecules that activate SIRT6 have already been reported. The weak point is translation. The theory needs optimized compounds to reach glaucoma-relevant tissue, engage SIRT6 in vivo, and produce disease-modifying effects, which the provided evidence has not yet shown for Galilei's specific series.
Supporting evidence: A 2024 publication reports that SIRT6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma.; Cellularly active SIRT6 allosteric activators have been identified.; Pyrrolo[1,2-a]quinoxaline derivatives have been designed and pharmacologically evaluated as potent and selective SIRT6 activators.; SIRT6 activation or restoration has protective effects in several non-ocular disease models.
Counter evidence: The evidence context does not show that Galilei's stabilized RM-13 analogs, MDL analogs, or CL5D compounds already have adequate exposure, selectivity, stability, or ocular pharmacokinetics.; The causal sufficiency claim in glaucoma remains an assumption: SIRT6 may be protective biology without being enough, by itself, to modify disease.
Explanatory power5.0
SIRT6 activation enhances DNA repair capacity
The company materials state that SIRT6 activation has DNA-repair effects, and the cited literature includes a report that SIRT6 activation rescues age-related decline in DNA damage repair in primary human chondrocytes. The causal theory is that pharmacologic SIRT6 activation improves maintenance of genomic integrity, which could counter age-associated cellular dysfunction.
Testable predictions are that treated cells or tissues should show improved DNA damage repair capacity, reduced accumulated DNA damage, and better survival or function after genotoxic or age-associated stress compared with controls.
The premise is biologically credible: SIRT6 has published links to DNA repair, aging biology, metabolism, and stress responses, and a 2023 study reports rescue of age-related DNA damage repair decline in primary human chondrocytes. The weak point is generalization. Chondrocytes are a real human primary-cell system, but they do not prove that pharmacologic SIRT6 activation improves genomic maintenance across tissues or in an organism.
Supporting evidence: A 2023 publication reports that SIRT6 activation rescues age-related decline in DNA damage repair in primary human chondrocytes.; The evidence set includes small-molecule SIRT6 activator work from 2018 and 2023, so the pharmacologic premise is concrete.; SIRT6 has broader links to aging-relevant biology, including lifespan regulation in male mice and healthy lifespan extension through energy homeostasis.
Counter evidence: The central DNA-repair evidence appears anchored mainly in primary human chondrocytes.; The theory assumes that better repair capacity will reduce accumulated DNA damage, which is plausible but still a separate empirical step.; SIRT6 affects multiple pathways, so observed benefits may come from stress, inflammatory, or metabolic effects rather than DNA repair alone.
Explanatory power5.0
The theory explains the chondrocyte repair finding directly: activate SIRT6, improve DNA damage repair. It explains the wider stress-resilience evidence less cleanly. Liver failure, retinal degeneration, wound healing, inflammation, angiogenesis, and metabolic homeostasis can all improve through routes that do not require improved DNA repair as the main driver. The theory is coherent, but it has not beaten the obvious alternative yet: SIRT6 is a broad stress-response regulator.
SIRT6 activation restores metabolic and mitochondrial homeostasis
Galilei's deck states that SIRT6 activation has mitochondrial and metabolic effects, and its cited longevity literature includes restoration of energy homeostasis by SIRT6 extending healthy lifespan. The causal theory is that SIRT6 activation improves cellular energy regulation and mitochondrial function, thereby supporting resilience in aging tissues and age-related disease.
Testable predictions are that SIRT6 activators should improve metabolic or mitochondrial readouts, such as energy homeostasis markers, mitochondrial stress resistance, or tissue function, and these changes should correlate with improved healthspan-relevant phenotypes in disease or aging models.
The premise is credible: SIRT6 has published links to energy homeostasis, lifespan regulation in male mice, and tissue protection in aging or disease models. The weak point is causal breadth. The evidence supports SIRT6 as a regulator of metabolism and stress responses, but it does not yet prove that pharmacologic SIRT6 activation restores mitochondrial homeostasis across aging tissues as a general rule.
Supporting evidence: A 2021 publication is titled "Restoration of energy homeostasis by SIRT6 extends healthy lifespan."; A 2012 study reports that SIRT6 regulates lifespan in male mice.; Small-molecule and allosteric SIRT6 activators have been reported, so the mechanism can be tested pharmacologically.; Disease-context studies link SIRT6 activation or preservation to retinal ganglion cell protection, diabetic HFpEF mitigation, cartilage biology, acute liver failure, and wound healing.
Counter evidence: The theory assumes that metabolic homeostasis, mitochondrial function, and tissue resilience are causally connected in SIRT6-linked aging phenotypes, rather than merely correlated.; The evidence context does not show equivalent lifespan or healthspan effects across both sexes, multiple species, or multiple independent activator chemotypes.; Some cited tissue benefits could arise through inflammation, DNA repair, IGF-1 signaling, or stress-response pathways rather than direct mitochondrial restoration.
SIRT6 activation reduces inflammatory damage
The company materials state that SIRT6 activation has anti-inflammatory effects, and the listed MDL-800 publication connects SIRT6 activation with suppression of inflammation through the NF-kB pathway. The implied mechanism is that activating SIRT6 dampens inflammatory signaling that contributes to tissue damage and age-related disease progression.
Testable predictions are that Galilei's SIRT6 activators or MDL-derived analogs should reduce NF-kB pathway activity and inflammatory markers in relevant disease models, including ocular neuroinflammation models if applied to glaucoma.
The premise is biologically credible: MDL-800 is reported to activate SIRT6 and suppress inflammation through NF-kB in mouse cutaneous wound healing, and separate 2024 reports connect SIRT6 activation with protection in acute liver failure and retinal ganglion cell degeneration. The weak point is generalization. A wound model, liver injury model, heart failure context, and glaucoma-relevant degeneration do not prove that Galilei's own activators will reduce inflammatory tissue damage across diseases.
Supporting evidence: MDL-800, a SIRT6 activator, suppresses inflammation through the NF-kB pathway in a mouse cutaneous wound healing context.; Hepatic SIRT6 activation is reported to abrogate acute liver failure.; SIRT6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma.
Counter evidence: The evidence context gives no direct data for Galilei's own SIRT6 activators.; The glaucoma link is partly inferential: SIRT6 protects retinal ganglion cells, but the supplied node does not show that this protection depends on NF-kB suppression in ocular neuroinflammation.
Explanatory power6.0
The theory explains a real cluster of observations: SIRT6 activation appears protective in inflammatory or stress-linked tissue injury, and NF-kB gives a plausible mechanism for lower inflammatory signaling. Still, the explanation is broader than the evidence. SIRT6 affects multiple cellular programs, so protection in liver, heart, retina, or wound healing could come through metabolism, DNA repair, angiogenesis, cell survival, or other pathways besides inflammation control.
SIRT6 activation restores DNA repair capacity
The materials state that SIRT6 activation has DNA-repair effects. The causal theory is that activating SIRT6 can counter age-associated decline in DNA damage repair, reducing accumulated cellular damage that contributes to degeneration and age-related disease.
This predicts that treated cells or tissues should show improved DNA damage repair markers, reduced persistence of DNA lesions after stress, and better maintenance of cell viability or tissue function in aging-relevant models.
The premise is credible. SIRT6 has direct links to DNA repair biology, and the evidence includes a 2023 study reporting rescue of age-related DNA damage repair decline in primary human chondrocytes. The theory also fits the broader aging premise that some aged cells and tissues lose repair capacity. The weak point is generality: chondrocytes are a real aging-relevant model, but they do not prove the same repair rescue across neurons, muscle, immune cells, kidney, or whole organisms.
Supporting evidence: SIRT6 activation is stated to have biologically relevant DNA-repair effects with high-confidence support from 2023, 2020, and 2018 publications.; A 2023 study reports that SIRT6 activation rescues age-related decline in DNA damage repair in primary human chondrocytes.; Small-molecule SIRT6 activators have been identified and pharmacologically evaluated, including cellularly active activators.
Counter evidence: The age-related decline in DNA repair is listed with medium confidence, which means the starting aging premise is plausible but tissue-dependent.; The theory assumes that chondrocyte repair effects generalize to other aging-relevant tissues, and that assumption is only medium confidence.
Explanatory power6.0
The theory explains the chondrocyte repair data well: if SIRT6 activation restores repair capacity, improved repair markers and fewer persistent lesions follow directly. It explains the broader degeneration findings less cleanly. SIRT6 affects inflammation, metabolism, angiogenesis, IGF-1 signaling, and energy homeostasis, so better tissue outcomes do not necessarily come from DNA repair. The theory is a good local explanation for repair phenotypes and a weaker explanation for whole-disease protection.
SIRT6 activation improves mitochondrial and metabolic resilience
Galilei's materials describe SIRT6 activation as producing mitochondrial and metabolic effects. The causal theory is that small-molecule SIRT6 activators may improve cellular energy handling and mitochondrial resilience, thereby helping stressed or aging tissues maintain function under disease conditions.
Testable predictions include improved mitochondrial function, restored energy-homeostasis markers, and better survival or functional outcomes in aged or metabolically stressed disease models treated with SIRT6 activators.
The premise is credible: SIRT6 has published links to energy homeostasis, lifespan biology, diabetic heart failure, liver failure, retinal degeneration, wound healing, DNA repair, and osteoarthritis models. The weak point is translation from SIRT6 biology to small-molecule activators. The evidence says activators can move relevant biology, but it does not yet prove that pharmacological activation reliably reproduces the full protective program in aged human tissues.
Supporting evidence: Restoration of energy homeostasis by SIRT6 extends healthy lifespan, 2021.; Identification of a cellularly active SIRT6 allosteric activator, 2018.; Design and pharmacological evaluation of potent and selective SIRT6 activators, 2023.; SIRT6 mitigates heart failure with preserved ejection fraction in diabetes, 2022.
Counter evidence: Several supportive observations involve SIRT6 function or activation in disease models, but not necessarily the same small-molecule activators Galilei would develop.; Some evidence supports broader aging resilience, such as DNA repair or IGF-1 effects, rather than the mitochondrial and metabolic mechanism directly.
Explanatory power6.0
The theory explains a real cluster: energy-homeostasis restoration, diabetic cardiac resilience, liver protection, retinal protection, and wound healing all fit a stress-resilience model. But the mitochondrial claim is doing more work than the evidence can carry. Inflammation control, angiogenesis, DNA repair, IGF-1 signaling, and tissue-specific survival pathways could explain parts of the same evidence without making mitochondrial resilience the central cause.
The supplied public evidence links Raul Mostoslavsky to SIRT6 and aging in general, but not to Galilei's specific claim that small-molecule SIRT6 activation protects retinal ganglion cells or the optic nerve in glaucoma. In this dossier, he is publicly associated with "SIRT6 and the Hallmarks of Aging," which is adjacent background, not a public endorsement or even a direct mention of the glaucoma neuroprotection theory.
The theory explains why SIRT6 activation is a plausible glaucoma therapy, but it does not yet explain the observed evidence better than simpler alternatives. The current evidence can also fit a weaker claim: SIRT6 is part of a protective stress-response network, and activating it may help in some models without becoming a practical drug program.
Supporting evidence: SIRT6 protection in retinal ganglion cells and optic nerve gives the theory a direct glaucoma-relevant anchor.; Existing allosteric activators show that SIRT6 can be modulated by small molecules rather than only by genetic manipulation.; MDL-800 shows pharmacological activity in mice, including NF-kB pathway modulation and wound-healing effects.
Counter evidence: The evidence does not yet connect optimized SIRT6 activators to retinal target engagement, preserved optic nerve function, or durable glaucoma modification.; Non-ocular effects in liver, cartilage, heart, wound healing, and lifespan models support broad SIRT6 biology, but they do not by themselves explain glaucoma efficacy.; Alternative explanations remain open, including model-specific stress resistance, pathway effects unrelated to direct SIRT6 activation, or compounds that work through mixed targets.
Falsifiability8.0
This is a strongly testable theory. It makes several clear failure points: chemistry may fail to improve potency or selectivity, ADME/PK may fail to produce adequate exposure, in vivo target engagement may be absent, and glaucoma models may show no retinal ganglion cell or optic nerve protection. That is real Popperian surface area.
Supporting evidence: The theory predicts improved SIRT6 activation potency and selectivity compared with earlier tool compounds.; It predicts acceptable exposure and drug-like pharmacokinetic profiles after ADME/PK optimization.; It predicts in vivo target engagement in disease-relevant tissues.; It predicts efficacy in glaucoma proof-of-concept models, including protection of retinal ganglion cells or optic nerve structure and function.
Counter evidence: Some thresholds are still underspecified: acceptable exposure, sufficient target engagement, and meaningful efficacy need quantitative cutoffs before the program can be cleanly killed or advanced.; The broader claim about other age-related diseases is looser and easier to preserve after a glaucoma failure.
Reasoning tree
project_implication
Optimized drug-like small-molecule SIRT6 activators could translate protective SIRT6 biology into disease-modifying therapy for glaucoma and potentially other age-related diseases.
medium confidence - 4 linked evidence items
premise
implies
SIRT6 activity is biologically protective in aging-related tissue degeneration and disease contexts.
high confidence - 5 linked evidence items
observation
observed_in
SIRT6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma.
high confidence - 1 linked evidence item
observation
observed_in
SIRT6 activation or restoration has protective effects in non-ocular disease models, including liver failure, cartilage aging, heart failure with preserved ejection fraction in diabetes, wound healing, and lifespan or healthspan models.
medium confidence - 6 linked evidence items
prediction
predicts
If the SIRT6 activator program succeeds in glaucoma, related optimized activators may have therapeutic potential in other age-related diseases where SIRT6 biology is protective.
low confidence - 5 linked evidence items
premise
requires
Small molecules can allosterically activate SIRT6 and show cellular or pharmacological activity.
high confidence - 4 linked evidence items
observation
observed_in
Cellularly active SIRT6 allosteric activators have been identified.
high confidence - 1 linked evidence item
observation
observed_in
Pyrrolo[1,2-a]quinoxaline-based derivatives have been designed and pharmacologically evaluated as potent and selective SIRT6 activators.
high confidence - 1 linked evidence item
observation
observed_in
MDL-800, a SIRT6 activator, suppresses inflammation through NF-kB pathway modulation and promotes angiogenesis in a mouse wound-healing model.
medium confidence - 1 linked evidence item
assumption
assumes
SIRT6 activation is causally sufficient to modify glaucoma-relevant degeneration rather than merely correlating with protective biology.
medium confidence - 1 linked evidence item
assumption
assumes
Medicinal chemistry can improve RM-13 analogs, MDL analogs, and CL5D-series compounds into drug-like molecules with adequate potency, selectivity, stability, exposure, and pharmacokinetics.
medium confidence - 3 linked evidence items
prediction
predicts
Medicinal chemistry optimization should yield SIRT6 activator compounds with improved activation potency and selectivity compared with earlier tool compounds.
medium confidence - 2 linked evidence items
prediction
predicts
ADME and pharmacokinetic optimization should produce candidate compounds with acceptable exposure and drug-like pharmacokinetic profiles.
medium confidence - 2 linked evidence items
derivation
implies
If SIRT6 is protective in glaucoma biology and small molecules can activate SIRT6 in cells or animals, then optimized SIRT6 activators are plausible therapeutic candidates for glaucoma.
medium confidence - 3 linked evidence items
prediction
predicts
Optimized SIRT6 activators should demonstrate in vivo target engagement in disease-relevant tissues.
medium confidence - 2 linked evidence items
prediction
predicts
Optimized SIRT6 activators should show efficacy in glaucoma proof-of-concept models, including protection of retinal ganglion cells or optic nerve structure and function.
medium confidence - 1 linked evidence item
premise
implies
Primary open-angle glaucoma has unmet needs in detection, monitoring, treatment, and disease understanding, creating a rationale for disease-modifying approaches beyond current care.
No public quotes, records, or publications are provided for Beth Werner. On this evidence, we cannot show that she endorses, mentions, or contradicts the theory, so the correct label is silence.
No public quotes, records, or publications were provided for David P. Al-Adra. On this evidence, there is no public endorsement, mention, or contradiction of the theory.
The evidence here does not show David Sinclair discussing Galilei, SIRT6, small-molecule SIRT6 activators, or the claim that medicinal chemistry optimization can turn SIRT6 activation into a glaucoma therapy. The quoted posts are about aging, epigenetic restoration, and life expectancy in general. That is too broad to count as a mention, endorsement, or contradiction of this specific company theory.
Public records tie John M. Denu to Galilei as a co-founder and place him in sirtuin and aging-related research, and the WARF item says Galilei is developing sirtuin drugs. That is a public mention of the general therapeutic direction. It does not show Denu explicitly endorsing the more specific company theory that medicinal chemistry optimization of small-molecule SIRT6 activators will deliver disease-modifying glaucoma therapy.
The supplied public evidence ties Guarente to sirtuin biology and aging research in general, and one source explicitly adds caution that findings in yeast do not automatically carry over to animals. It does not show him publicly endorsing, describing, or disputing Galilei's specific theory that optimized small-molecule SIRT6 activators can become disease-modifying therapies for glaucoma.
mentions
Mostoslavsky is publicly tied to SIRT6, aging, and epigenetics, which lines up with the biological premise behind Galilei's program. But the provided evidence does not show him publicly endorsing the specific claim that optimized small-molecule SIRT6 activators can achieve the exposure, selectivity, PK, and glaucoma efficacy needed for a disease-modifying therapy.
Supporting evidence: The chondrocyte publication matches the theory's core prediction: treated cells should show improved DNA damage repair capacity.; Related SIRT6 studies report protection in aging or stress-associated systems, including retina, liver, skin wound healing, and metabolic homeostasis.; The reasoning graph correctly separates direct repair claims from broader implications about genomic integrity and cellular dysfunction.
Counter evidence: Several cited disease or tissue benefits do not, from the supplied evidence, specifically show that DNA repair caused the functional improvement.; Inflammation, NF-kB signaling, angiogenesis, and energy homeostasis are plausible alternative mechanisms for some observed benefits.; We do not fully understand from this evidence whether reduced accumulated DNA damage follows from the measured repair-capacity changes.
Falsifiability8.0
This theory is testable in a Popperian sense. It predicts measurable changes: faster repair after induced DNA damage, lower residual damage markers, and better survival or function after genotoxic or age-associated stress. A clean failure would be straightforward: a selective SIRT6 activator reaches the cells, activates SIRT6, and still does not improve repair kinetics or reduce damage compared with controls.
Supporting evidence: The stated predictions include improved DNA damage repair capacity compared with controls.; The theory predicts reduced accumulated DNA damage in treated cells or tissues.; The theory predicts better survival or function after genotoxic or age-associated stress.
Counter evidence: The predictions need assay-level thresholds before they become decisive, such as repair kinetics, comet assay readouts, gamma-H2AX resolution, or survival effect sizes.; Because SIRT6 has multiple functions, a functional benefit alone would not prove the DNA-repair mechanism.; A null result could be blamed on compound potency, exposure, tissue context, or assay choice unless those controls are locked down.
Reasoning tree
premise
Pharmacologic activation of SIRT6 has DNA-repair-related effects that may be relevant to age-associated cellular dysfunction.
medium confidence - 3 linked evidence items
observation
observed_in
SIRT6 activation was reported to rescue age-related decline in DNA damage repair in primary human chondrocytes.
high confidence - 1 linked evidence item
premise
requires
Small-molecule SIRT6 activators can be identified and pharmacologically evaluated as selective SIRT6 activators.
medium confidence - 3 linked evidence items
derivation
implies
If SIRT6 activation improves DNA damage repair, then it should help maintain genomic integrity under aging or genotoxic stress.
medium confidence - 2 linked evidence items
assumption
assumes
DNA-repair effects observed in primary human chondrocytes generalize to other relevant cell or tissue contexts.
medium confidence - 1 linked evidence item
assumption
assumes
Improved DNA damage repair is sufficient to reduce accumulated DNA damage in treated cells or tissues.
medium confidence - 1 linked evidence item
derivation
implies
Better maintenance of genomic integrity could counter age-associated cellular dysfunction.
medium confidence - 3 linked evidence items
prediction
predicts
Cells or tissues treated with a SIRT6 activator should show better survival or function after genotoxic or age-associated stress compared with controls.
medium confidence - 4 linked evidence items
project_implication
implies
A SIRT6-activating intervention should be evaluated for whether it improves genomic maintenance and stress resilience in disease- or aging-relevant experimental systems.
medium confidence - 3 linked evidence items
prediction
predicts
Cells or tissues treated with a SIRT6 activator should show improved DNA damage repair capacity compared with controls.
high confidence - 1 linked evidence item
prediction
predicts
Cells or tissues treated with a SIRT6 activator should show reduced accumulated DNA damage compared with controls.
No public quotes, records, or publications are provided for Beth Werner. On this evidence, there is no basis to say she endorses, mentions, or contradicts the SIRT6 DNA-repair theory.
There is no public evidence here linking David P. Al-Adra to this SIRT6 and DNA-repair theory. No quotes, records, or publications are provided, so the only defensible call is silence.
The provided public statements do not mention SIRT6, DNA repair capacity, genomic integrity, or a claim that SIRT6 activation improves repair of age-related damage. Sinclair talks here about aging, epigenetic restoration, and cellular information loss, which is adjacent to the broader field but not this theory.
The provided public evidence ties John M. Denu to Galilei Biosciences and to broad work on epigenetics, aging, and sirtuins, but it does not show him publicly stating that SIRT6 activation improves DNA repair capacity. The closest item is the WARF post about sirtuins and Galilei's drug work, which is broader than this theory.
The provided public evidence links Leonard P. Guarente to aging research and to sirtuins broadly, but it does not show him publicly discussing SIRT6 activation, DNA repair capacity, or the specific claim that pharmacologic SIRT6 activation improves genomic maintenance. On this record, he stays silent on the theory itself.
silent
The public evidence here links Raul Mostoslavsky to SIRT6, aging, and epigenetics in general, but it does not show him publicly stating that SIRT6 activation improves DNA repair capacity or otherwise addressing this specific company theory. On this record, he stays silent on the claim itself.
Explanatory power6.0
The theory explains a real cluster of findings: SIRT6 touches energy regulation, stress resistance, and tissue function. It is less strong as an explanation of the whole evidence set because SIRT6 is pleiotropic. DNA repair, inflammation control, NF-kB signaling, angiogenesis, and tissue-specific gene regulation can explain several observations without requiring a single mitochondrial-homeostasis mechanism.
Supporting evidence: The energy-homeostasis lifespan paper fits the central claim directly.; The diabetic HFpEF, glaucoma, osteoarthritis, liver failure, and wound-healing studies fit the broader claim that SIRT6 supports tissue resilience in disease contexts.; The theory predicts paired improvement in metabolic or mitochondrial readouts and healthspan-relevant phenotypes, which matches the proposed testing logic.
Counter evidence: The wound-healing study names NF-kB suppression and angiogenesis, which may be downstream immune and vascular effects rather than primary mitochondrial repair.; The chondrocyte and cartilage evidence includes DNA damage repair and IGF-1 biology, which are plausible alternative mechanisms.; The provided context does not show that mitochondrial readouts mediate the observed tissue benefits.
Falsifiability8.0
This theory is testable. A SIRT6 activator should improve defined metabolic or mitochondrial readouts, such as energy homeostasis markers, mitochondrial stress resistance, or tissue function, and those changes should track with healthspan-relevant outcomes. The clean falsifier is simple: activate SIRT6, confirm target engagement, then see no metabolic or mitochondrial improvement, or see tissue benefit with no relationship to those readouts.
Supporting evidence: The theory names concrete prediction classes: energy homeostasis markers, mitochondrial stress resistance, tissue function, and healthspan-relevant phenotypes.; Published SIRT6 activators make dose-response, target-engagement, and loss-of-function tests feasible.; The theory can be challenged in aging and disease models by comparing activator effects against SIRT6-deficient or SIRT6-insensitive systems.
Counter evidence: The prediction is still broad unless each experiment pre-specifies the tissue, activator, mitochondrial metric, metabolic metric, and healthspan endpoint.; Correlation between mitochondrial readouts and tissue function would not by itself prove causality.; Pleiotropic SIRT6 biology could let the theory survive too many negative results unless strict falsification criteria are set in advance.
Reasoning tree
premise
SIRT6 activation is proposed to restore metabolic and mitochondrial homeostasis in aging or disease contexts.
high confidence - 3 linked evidence items
observation
observed_in
Published longevity literature reports that restoration of energy homeostasis by SIRT6 extends healthy lifespan.
high confidence - 1 linked evidence item
observation
observed_in
SIRT6 has been reported to regulate lifespan in male mice.
medium confidence - 1 linked evidence item
premise
requires
Small-molecule SIRT6 activators exist and can be evaluated pharmacologically as selective or allosteric activators.
high confidence - 3 linked evidence items
derivation
implies
If SIRT6 activation restores energy homeostasis, then activating SIRT6 should improve cellular energy regulation and mitochondrial function.
medium confidence - 2 linked evidence items
assumption
assumes
Metabolic homeostasis, mitochondrial function, and tissue resilience are causally connected rather than merely correlated in SIRT6-associated aging phenotypes.
medium confidence - 2 linked evidence items
derivation
implies
Improved cellular energy regulation and mitochondrial function should support resilience in aging tissues and age-related disease models.
medium confidence - 4 linked evidence items
observation
observed_in
SIRT6 activation or preservation is associated with protection or improved function in age-related tissue disease contexts including glaucoma, diabetic heart failure with preserved ejection fraction, osteoarthritis-related cartilage biology, acute liver failure, and wound healing.
medium confidence - 5 linked evidence items
prediction
predicts
SIRT6 activators should improve metabolic or mitochondrial readouts such as energy homeostasis markers, mitochondrial stress resistance, or tissue function.
high confidence - 3 linked evidence items
prediction
predicts
The metabolic or mitochondrial improvements caused by SIRT6 activation should correlate with improved healthspan-relevant phenotypes in disease or aging models.
medium confidence - 4 linked evidence items
project_implication
implies
Testing SIRT6 activators should prioritize assays that jointly measure metabolic or mitochondrial readouts and healthspan-relevant tissue outcomes in aging or disease models.
high confidence - 4 linked evidence items
assumption
assumes
Provided publications about unrelated nuclear physics, dark matter, and cosmic-ray spectra are not relevant evidence for the SIRT6 activation theory.
Silent. The provided evidence includes no quotes, records, or publications from Beth Werner about SIRT6 activation, mitochondrial homeostasis, or the company's theory, so there is no public basis here to classify her as endorsing, mentioning, or contradicting it.
No public quotes, records, or publications are provided for David P. Al-Adra that mention or support this SIRT6 activation theory. With the evidence here, the correct classification is silence.
The provided evidence does not show David Sinclair publicly discussing SIRT6 activation, mitochondrial homeostasis, metabolic regulation, or Galilei's specific causal theory. The quotes here are about cancer's effect on life expectancy, loss of cellular information, biological aging, immortality framing, and epigenetic restoration by ER-100. That is adjacent aging rhetoric, not a public statement on this theory.
The provided public evidence links John M. Denu to Galilei as a co-founder and shows that his research covers metabolism, epigenetics, and mitochondrial regulation. It also says Galilei is developing sirtuin drugs. What it does not show is a public statement from Denu that specifically endorses, explains, or disputes the theory that SIRT6 activation restores metabolic and mitochondrial homeostasis.
The provided public evidence links Leonard Guarente to aging biology, sirtuins in general, and Galilei as a founder, but it does not show him publicly endorsing, describing, or disputing this specific claim: that SIRT6 activation restores metabolic and mitochondrial homeostasis. A general lecture on NAD and sirtuins is too broad to count as support for this exact SIRT6 mechanism.
mentions
Mostoslavsky is publicly tied to SIRT6, aging, and metabolism through talks titled "Linking Aging and Metabolism to Epigenetics" and "SIRT6 and The Hallmarks of Aging." That is a public mention of the theory’s core topic area, but this evidence does not show him explicitly endorsing the specific claim that SIRT6 activation restores metabolic and mitochondrial homeostasis.
Supporting evidence: The MDL-800 publication directly connects SIRT6 activation with NF-kB pathway suppression and reduced inflammation in mice.; The liver failure and retinal degeneration observations fit a protective SIRT6 activity model.; The derived prediction links SIRT6 activation to measurable reductions in inflammatory pathway activity and downstream markers.
Counter evidence: The diabetes-associated heart failure evidence supports tissue protection, but the supplied context does not tie that effect specifically to NF-kB or inflammatory damage.; SIRT6 has known roles outside inflammation, so the same observations may have alternative mechanistic explanations.
Falsifiability8.0
This theory can be tested cleanly. If Galilei's activators or MDL-derived analogs fail to reduce NF-kB pathway activity, inflammatory cytokines, or tissue damage in relevant inflammatory disease models, the core claim takes a direct hit. The glaucoma extension is also testable in ocular neuroinflammation models. The theory would be stronger if it named effect sizes, dosing windows, cell types, and disease models up front.
Supporting evidence: The stated prediction requires reduced NF-kB pathway activity in relevant inflammatory disease models.; The stated prediction requires reduced inflammatory markers in relevant disease models.; For glaucoma, the prediction specifies reduced NF-kB pathway activity and inflammatory markers in ocular neuroinflammation models.
Counter evidence: No quantitative threshold is given for how much NF-kB activity or inflammatory markers must fall.; The theory does not specify which Galilei compounds, which models, or which inflammatory markers would count as decisive tests.
Reasoning tree
premise
SIRT6 activation can reduce inflammatory damage by dampening inflammatory signaling that contributes to tissue damage and age-related disease progression.
medium confidence - 3 linked evidence items
observation
observed_in
MDL-800, a SIRT6 activator, suppresses inflammation through the NF-kB pathway in a mouse cutaneous wound healing context.
high confidence - 1 linked evidence item
derivation
implies
If SIRT6 activation suppresses NF-kB signaling, then SIRT6 activators should reduce inflammatory pathway activity and downstream inflammatory markers in disease models.
high confidence - 1 linked evidence item
assumption
assumes
The anti-inflammatory NF-kB effects observed for MDL-800 will generalize to Galilei's SIRT6 activators or MDL-derived analogs.
medium confidence - 3 linked evidence items
prediction
predicts
Galilei's SIRT6 activators or MDL-derived analogs should reduce NF-kB pathway activity in relevant inflammatory disease models.
medium confidence - 2 linked evidence items
project_implication
requires
Galilei should prioritize assays that measure NF-kB pathway activity and inflammatory markers when evaluating SIRT6 activators for inflammatory damage and glaucoma-related applications.
medium confidence - 2 linked evidence items
prediction
predicts
Galilei's SIRT6 activators or MDL-derived analogs should reduce inflammatory markers in relevant disease models.
medium confidence - 2 linked evidence items
observation
observed_in
Hepatic SIRT6 activation is reported to abrogate acute liver failure, supporting a protective role for SIRT6 activation in inflammatory tissue injury.
medium confidence - 1 linked evidence item
observation
observed_in
SIRT6 mitigates diabetes-associated heart failure with preserved ejection fraction, suggesting SIRT6 activity can protect against disease-associated tissue dysfunction.
medium confidence - 1 linked evidence item
observation
observed_in
SIRT6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma.
medium confidence - 1 linked evidence item
derivation
implies
Because glaucoma involves retinal ganglion cell and optic nerve degeneration, SIRT6 activation may be relevant to ocular neuroinflammation and glaucoma-related tissue damage.
medium confidence - 2 linked evidence items
prediction
predicts
If applied to glaucoma, SIRT6 activators should reduce NF-kB pathway activity and inflammatory markers in ocular neuroinflammation models.
No public quotes, records, or publications were provided that show Beth Werner endorsing, mentioning, or contradicting the claim that SIRT6 activation reduces inflammatory damage. On this evidence, the public record is silent.
There is no public quote, record, or publication here linking David P. Al-Adra to this SIRT6 anti-inflammatory theory. With no evidence in the dossier, the correct call is silence, not inference.
The supplied public quotes discuss calorie restriction, epigenetic information loss, aging as noise, and gene-expression drift. None mention SIRT6, small-molecule SIRT6 activation, inflammatory damage, glaucoma, or the claim that SIRT6 activation reduces inflammation-driven tissue injury.
The supplied evidence ties John Denu to epigenetics, metabolism, signaling, and a company developing sirtuin drugs, but none of it shows him publicly stating that SIRT6 activation reduces inflammatory damage. That is a specific mechanistic claim, and this dossier does not document him endorsing, discussing, or disputing it directly.
The supplied public evidence ties Leonard Guarente to aging, neurodegeneration, and sirtuin research in broad terms, but it does not show him publicly discussing the specific claim that SIRT6 activation reduces inflammatory damage. A general talk on NAD and sirtuins is too broad to count as an endorsement or contradiction of this theory.
silent
The provided public evidence links Raul Mostoslavsky to SIRT6, aging, metabolism, and epigenetics, but it does not show him publicly stating that SIRT6 activation reduces inflammatory damage or that small-molecule SIRT6 activators should protect tissue by lowering inflammatory signaling. On this specific theory, the dossier is silent.
Supporting evidence: SIRT6 activation rescues age-related DNA damage repair decline in primary human chondrocytes.; The theory predicts improved DNA damage repair markers and reduced lesion persistence after genotoxic or aging-relevant stress.; SIRT6 activity is associated with protection or improved outcomes in aging-relevant models including retinal or optic nerve degeneration, osteoarthritis, diabetic heart failure with preserved ejection fraction, and healthy lifespan.
Counter evidence: The evidence context flags low confidence for the claim that disease-model protection is mediated by DNA repair rather than inflammation, metabolism, angiogenesis, or IGF-1 signaling.; Several supporting disease-model studies concern outcomes where DNA repair may be only one contributor, or may not be the measured driver at all.
Falsifiability9.0
This theory is highly testable. It predicts specific readouts: DNA repair markers should improve after SIRT6 activation, DNA lesions should clear faster after stress, and viability or tissue function should hold up better in aging-relevant models. A clean failure would be simple: activate SIRT6, confirm target engagement, then see no improvement in repair kinetics or lesion persistence compared with controls. That would damage the central claim, not just a side detail.
Supporting evidence: The theory predicts improved DNA damage repair markers in treated cells or tissues compared with untreated controls.; It predicts reduced persistence of DNA lesions after genotoxic or aging-relevant stress.; It predicts better maintenance of cell viability or tissue function in aging-relevant disease models.
Counter evidence: Some downstream disease outcomes could be rescued by non-repair pathways, so tissue-function benefits alone would not strongly test the DNA-repair mechanism.; A negative result with one SIRT6 activator could reflect compound failure unless target engagement and SIRT6 dependence are measured.
Reasoning tree
premise
SIRT6 activation has biologically relevant DNA-repair effects.
high confidence - 3 linked evidence items
premise
assumes
Aging is associated with reduced DNA damage repair capacity in some cell types and tissues.
medium confidence - 1 linked evidence item
observation
observed_in
SIRT6 activation rescues age-related decline in DNA damage repair in primary human chondrocytes.
high confidence - 1 linked evidence item
premise
requires
Small-molecule SIRT6 activators can activate SIRT6 in cellular or pharmacological contexts.
high confidence - 3 linked evidence items
derivation
implies
If SIRT6 activation improves DNA repair capacity, then activating SIRT6 may counter age-associated accumulation of unrepaired DNA lesions.
medium confidence - 2 linked evidence items
derivation
implies
Reducing persistent DNA damage may reduce cellular dysfunction that contributes to degeneration and age-related disease.
medium confidence - 5 linked evidence items
observation
observed_in
SIRT6 activity is associated with protection or improved outcomes in aging-relevant degeneration models, including retinal or optic nerve degeneration, osteoarthritis, heart failure with preserved ejection fraction in diabetes, and healthy lifespan.
medium confidence - 5 linked evidence items
prediction
predicts
SIRT6 activation should improve maintenance of cell viability or tissue function in aging-relevant disease models.
medium confidence - 4 linked evidence items
assumption
assumes
The protective effects of SIRT6 activation in degeneration or disease models are at least partly mediated by improved DNA repair rather than only by unrelated pathways such as inflammation, metabolism, angiogenesis, or IGF-1 signaling.
low confidence - 3 linked evidence items
prediction
predicts
Cells or tissues treated with SIRT6 activators should show improved DNA damage repair markers compared with untreated controls.
high confidence - 1 linked evidence item
project_implication
implies
A useful evaluation program should test SIRT6 activators in aging-relevant models using DNA repair markers, lesion persistence after stress, and downstream viability or tissue-function outcomes.
high confidence - 3 linked evidence items
prediction
predicts
After genotoxic or aging-relevant stress, SIRT6-activated cells should show reduced persistence of DNA lesions.
medium confidence - 1 linked evidence item
assumption
assumes
The DNA-repair benefits observed in chondrocytes or specific disease models generalize to other aging-relevant cells and tissues.
There is no public evidence here. The evidence set contains no quotes, records, or publications linking Beth Werner to this SIRT6 and DNA-repair theory, so the defensible classification is silence rather than endorsement, mention, or contradiction.
There is no public evidence provided here: no quotes, records, or publications linking David P. Al-Adra to this SIRT6/DNA-repair theory. On this record, the defensible call is silence, not endorsement or contradiction.
The provided public evidence does not show David Sinclair discussing SIRT6 activation or the specific claim that it restores DNA repair capacity. His recent statements here focus on calorie restriction, epigenetic information loss, gene-expression drift, and aging as reducible systemic disorder. That is adjacent to aging biology, but it is not a public endorsement, mention, or contradiction of this SIRT6 DNA-repair theory.
The record supports John M. Denu's role as a Galilei co-founder and aging-related researcher, and one public post says Galilei is developing sirtuin drugs. It does not show Denu publicly endorsing, explaining, or disputing the specific claim that SIRT6 activation restores DNA repair capacity. On this theory, he is publicly silent in the provided evidence.
The provided evidence links Leonard P. Guarente to aging biology, sirtuins, and rejuvenation research in general, but it does not show a public statement from him specifically endorsing, discussing, or rejecting the claim that SIRT6 activation restores DNA repair capacity. General involvement in sirtuin research is not enough to count as a direct mention of this theory.
mentions
Mostoslavsky is publicly tied to the topic through a talk explicitly titled "SIRT6 and The Hallmarks of Aging." That supports public mention of SIRT6 in aging, but the provided evidence does not show him explicitly endorsing the narrower causal claim that SIRT6 activation restores DNA repair capacity, and it does not show a contradiction either.
Supporting evidence: Reported restoration of energy homeostasis by SIRT6 directly matches the theory's metabolic-resilience claim.; Diabetic heart failure with preserved ejection fraction is a metabolically stressed disease context, so SIRT6 benefit there supports the main causal direction.; Acute liver failure and aging or glaucoma-related optic nerve degeneration show functional protection under tissue stress.
Counter evidence: MDL-800 wound-healing data support inflammation suppression and angiogenesis, but the evidence node says this is not specifically mitochondrial resilience.; SIRT6 rescue of DNA damage repair supports aging resilience, but it is indirect support for the mitochondrial and metabolic mechanism.; Cartilage-specific Sirt6 deficiency worsening osteoarthritis could reflect IGF-1 and tissue-maintenance biology rather than improved energy handling.
Falsifiability8.0
The theory is testable in a clean Popperian sense. It predicts measurable changes: mitochondrial function, energy-homeostasis markers, and survival or tissue function in aged or metabolically stressed models after SIRT6 activator treatment. A strong failure pattern would hurt the theory: target engagement without improved mitochondrial readouts, no restoration of energy markers, or no functional benefit in properly stressed models.
Supporting evidence: The stated predictions include improved mitochondrial function versus untreated controls.; The theory predicts restoration of energy-homeostasis markers in aged or metabolically stressed models.; The theory predicts better survival, tissue function, or disease outcomes under stress.
Counter evidence: Some predictions are broad, especially survival or disease outcomes, so a failed model could be blamed on dose, tissue exposure, timing, or disease context.; The current evidence context does not specify quantitative thresholds for mitochondrial improvement or energy-homeostasis rescue.
Reasoning tree
premise
Small-molecule activation of SIRT6 can produce mitochondrial and metabolic effects relevant to cellular stress resilience.
medium confidence - 4 linked evidence items
assumption
assumes
Pharmacological SIRT6 activators can reproduce enough of SIRT6's protective biology in cells or tissues to be therapeutically meaningful.
medium confidence - 3 linked evidence items
derivation
implies
If SIRT6 activation restores energy homeostasis, then treated cells should better maintain energy handling during aging or disease stress.
medium confidence - 2 linked evidence items
derivation
implies
Improved cellular energy handling is expected to increase mitochondrial resilience under metabolic or inflammatory stress.
medium confidence - 3 linked evidence items
prediction
predicts
Disease or aging models treated with SIRT6 activators should show improved mitochondrial function compared with untreated controls.
medium confidence - 2 linked evidence items
project_implication
requires
A development program should prioritize SIRT6 activators that demonstrate restored energy-homeostasis markers, mitochondrial-function improvements, and functional benefit in aged or metabolically stressed disease models.
medium confidence - 3 linked evidence items
prediction
predicts
SIRT6 activator treatment should improve survival, tissue function, or disease outcomes in stressed or aging disease models.
medium confidence - 4 linked evidence items
observation
observed_in
SIRT6 mitigation of diabetic heart failure with preserved ejection fraction is consistent with improved resilience in a metabolically stressed disease model.
medium confidence - 1 linked evidence item
observation
observed_in
Hepatic SIRT6 activation abrogating acute liver failure is consistent with SIRT6 activation improving survival or function under severe tissue stress.
medium confidence - 1 linked evidence item
observation
observed_in
SIRT6 protection of retinal ganglion cells and optic nerve during aging and glaucoma is consistent with tissue resilience benefits in aging-associated disease.
medium confidence - 1 linked evidence item
observation
observed_in
MDL-800 suppression of inflammation and promotion of angiogenesis during wound healing supports a broader stress-resilience effect of SIRT6 activation, though not specifically mitochondrial resilience.
medium confidence - 1 linked evidence item
prediction
predicts
SIRT6 activator treatment should restore energy-homeostasis markers in aged or metabolically stressed models.
high confidence - 1 linked evidence item
observation
observed_in
Reported restoration of energy homeostasis by SIRT6 is consistent with the theory that SIRT6 activation supports metabolic resilience and healthy lifespan.
high confidence - 1 linked evidence item
observation
observed_in
SIRT6 activation rescuing age-related decline in DNA damage repair supports an aging-resilience role, but it is indirect support for the mitochondrial and metabolic mechanism.
medium confidence - 1 linked evidence item
observation
observed_in
Cartilage-specific Sirt6 deficiency worsening osteoarthritis severity and repressing IGF-1 supports the idea that loss of SIRT6 impairs tissue maintenance in disease contexts.
No public quotes, records, or publications are provided for Beth Werner. With no evidence tying her to this SIRT6 theory, the defensible call is silence rather than endorsement, mention, or contradiction.
No public quotes, records, or publications were provided that tie David P. Al-Adra to this SIRT6 activation theory. With no evidence in the dossier, the defensible classification is silence rather than endorsement, mention, or contradiction.
The provided public evidence does not mention SIRT6, mitochondrial resilience, metabolic resilience, or Galilei's small-molecule SIRT6 activator theory. Sinclair's quotes support broad claims about slowing or reversing aspects of aging, but that is not a public endorsement of this specific mechanism.
The public evidence ties John M. Denu to Galilei as a co-founder and shows his research focus on metabolism, epigenetics, and mitochondrial regulation, but none of the cited materials has him publicly stating or backing the specific claim that SIRT6 activation improves mitochondrial and metabolic resilience. The record supports involvement, not a public endorsement of this theory.
The provided evidence ties Leonard P. Guarente to aging research, sirtuins in general, and Galilei as a founder, but it does not show a public statement from him on this specific theory: that SIRT6 activation improves mitochondrial and metabolic resilience. A general lecture on NAD and sirtuins is too broad to count as endorsement of this narrower causal claim.
mentions
Mostoslavsky publicly discusses SIRT6, aging, metabolism, and epigenetics, so he is not silent on the scientific area. But this evidence does not show him explicitly endorsing Galilei's narrower causal claim that small-molecule SIRT6 activation improves mitochondrial and metabolic resilience in stressed or aging tissues.
